New data presented at the ongoing European Congress of Diabetology in Milan confirm the safety and efficacy of orforglipron, Lilly's first oral GLP-1 agonist. At the 2026 EASD (European Association ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results